These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38864273)

  • 1. Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors.
    Chun C; Song L; Xu G; Shi Q; Li F; Jia X
    J Surg Oncol; 2024 Jul; 130(1):47-55. PubMed ID: 38864273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
    Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
    Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL; Wei XJ; Zhang QC; Li F
    Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
    Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
    Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
    Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
    Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcome of laparoscopic surgery, including laparoendoscopic single-site surgery, for retroperitoneal paraganglioma compared with adrenal pheochromocytoma.
    Hattori S; Miyajima A; Hirasawa Y; Kikuchi E; Kurihara I; Miyashita K; Shibata H; Nakagawa K; Oya M
    J Endourol; 2014 Jun; 28(6):686-92. PubMed ID: 24499341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
    Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
    Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
    Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
    Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
    Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
    Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
    Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal paragangliomas with immunohistochemical deficiency of succinate dehydrogenase subunit B.
    Kimura N; Ishikawa M; Shigematsu K
    Endocr J; 2022 May; 69(5):523-528. PubMed ID: 34853215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.